- SINOVAC Biotech Ltd. (SVA, Financial) urges shareholders to vote "AGAINST" Proposals 1 and 2 via the WHITE proxy card before the Special Meeting.
- Leading proxy advisory firms ISS and Glass Lewis recommend retaining the current board.
- The Special Meeting will be held virtually on July 9, 2025, due to limited venue capacity.
The Board of Directors of SINOVAC Biotech Ltd. (SVA), a prominent Chinese biopharmaceutical company, is reminding its shareholders of the imminent voting deadline for the Special Meeting scheduled for July 9, 2025. Shareholders are strongly advised to vote on the WHITE proxy card "AGAINST" the reconstitution of the board as proposed in Proposals 1 and 2.
Esteemed independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass, Lewis & Co., have both advocated for shareholders to retain the existing board by opposing the proposed changes. The current board is noted for its ongoing efforts to pay fair dividends and restore trading stability, while the opposing group's proposals have been criticized for their lack of consistency and credibility.
Due to the limited capacity of the physical meeting venue, shareholders are encouraged to participate in the Special Meeting electronically. Registration for the virtual meeting is mandatory and must be completed by 8:00 p.m. Atlantic Standard Time on July 7, 2025. Instructions for participation will be provided upon successful registration.
SINOVAC Biotech Ltd. continues to focus on the development and commercialization of vaccines including its COVID-19 vaccine, CoronaVac®, which has gained approval in over 60 countries. The company is engaged in expanding its market opportunities across the globe.
